SLC5A2 and heart failure: The principal findings from our study are that SGLT2 inhibitor use was associated with the following: (a) a 30% lower risk of incident heart failure; (b) a significantly lower risk of AF and cardiac arrests, but not ventricular arrhythmias; and (c) a significant reduction in the risk of other secondary outcome events, such as all‐cause mortality, ischaemic strokes/TIA and the composite of arterial and venous thrombotic events.